Live Chat: The Future of Personalized Medicine

2021 ◽  
Keyword(s):  
Personalized Medicine ◽  
Live Chat ◽  
The Future

scholarly journals Current State of “Omics” Biomarkers in Pancreatic Cancer

2021 ◽  
Vol 11 (2) ◽  
pp. 127 ◽  
Author(s):  
Beste Turanli ◽  
Esra Yildirim ◽  
Gizem Gulfidan ◽  
Kazim Yalcin Arga ◽  
Raghu Sinha
Keyword(s):  
Pancreatic Cancer ◽  
Personalized Medicine ◽  
Biomarker Discovery ◽  
Survival Rates ◽  
Postoperative Recurrence ◽  
Molecular Biomarkers ◽  
Background Information ◽  
Current State ◽  
Pancreatic Cancer Screening ◽  
The Future

Pancreatic cancer is one of the most fatal malignancies and the seventh leading cause of cancer-related deaths related to late diagnosis, poor survival rates, and high incidence of metastasis. Unfortunately, pancreatic cancer is predicted to become the third leading cause of cancer deaths in the future. Therefore, diagnosis at the early stages of pancreatic cancer for initial diagnosis or postoperative recurrence is a great challenge, as well as predicting prognosis precisely in the context of biomarker discovery. From the personalized medicine perspective, the lack of molecular biomarkers for patient selection confines tailored therapy options, including selecting drugs and their doses or even diet. Currently, there is no standardized pancreatic cancer screening strategy using molecular biomarkers, but CA19-9 is the most well known marker for the detection of pancreatic cancer. In contrast, recent innovations in high-throughput techniques have enabled the discovery of specific biomarkers of cancers using genomics, transcriptomics, proteomics, metabolomics, glycomics, and metagenomics. Panels combining CA19-9 with other novel biomarkers from different “omics” levels might represent an ideal strategy for the early detection of pancreatic cancer. The systems biology approach may shed a light on biomarker identification of pancreatic cancer by integrating multi-omics approaches. In this review, we provide background information on the current state of pancreatic cancer biomarkers from multi-omics stages. Furthermore, we conclude this review on how multi-omics data may reveal new biomarkers to be used for personalized medicine in the future.

scholarly journals The future of personalized medicine

2016 ◽  
Vol 85 (1) ◽  
Author(s):  
Ramona Neferu ◽  
Alice Yi
Keyword(s):  
Clinical Pharmacology ◽  
Personalized Medicine ◽  
Medical Research ◽  
Clinical Investigation ◽  
Health Sciences ◽  
The Future ◽  
London Health ◽  
The Way

Dr Richard Kim is currently a professor and the chair of the Division of Clinical Pharmacology at Western University and the Director for the Centre for Clinical Investigation and Therapeutics at the London Health Sciences Centre (LHSC). He also holds the Wolfe Medical Research Chair in Pharmacogenomics and is at the forefront of advancing the specialty of clinical pharmacology—a growing field that promises to change the way we deliver healthcare in Canada and abroad. Dr Kim shared his insights into the future of personalized medicine and his roles as a clinician, researcher, administrator, and teacher.

Sign in / Sign up

Export Citation Format

Share Document